Number of Orphan Medicines to Grow in Europe as ‘Big Pharma’ Takes an Interest Says New Report from URCH Publishing
12/9/2011 6:25:11 AM
LONDON--(BUSINESS WIRE)--The number of medicines designated and marketed with an orphan status will grow steadily in Europe says a new report. Orphan Drug Markets in Europe - Key developments and the strategies of major pharmaceutical companies published by URCH Publishing, a business information provider, says that the commercial success of many orphans over the last ten years is boosting interest from Big Pharma as their blockbuster model becomes unsustainable. Already a number of major companies have reassessed their strategy with respect to orphan drugs and five of the top ten have made explicit commitments to the development of such drugs.
comments powered by